By Karunjit Singh ( January 9, 2024, 4:49 PM EST) -- The Federal Court of Appeal has deemed an invalidity defence raised by a generic drug manufacturer in a patent dispute an abuse of process, citing the company's prior unsuccessful non-infringement claim in a related proceeding involving the same drug....